Read More

What’s Going On With Pfizer On Thursday? Pharma Giant’s Shares Tick Lower

Pfizer Inc. reported that its Phase 3 CIFFREO study on Duchenne muscular dystrophy (DMD) gene therapy did not meet its primary effectiveness goal. Despite efforts to improve motor functions in boys aged 4 to 7 using a modified human dystrophin gene, the trial showed no significant progress, affecting Pfizer's quest for new treatments as it diversifies beyond its COVID-19 portfolio.

PFE

Read More

Cardiol Therapeutics Presented Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx For Recurrent Pericarditis; Administration Of CardiolRx Led To A Marked Reduction In The Primary Efficacy Endpoint Of Pericarditis Pain

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have

CRDL